Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 12.00
ALXN's Cash to Debt is ranked lower than
57% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. ALXN: 12.00 )
Ranked among companies with meaningful Cash to Debt only.
ALXN' s 10-Year Cash to Debt Range
Min: 0.49  Med: 3.26 Max: No Debt
Current: 12
Equity to Asset 0.80
ALXN's Equity to Asset is ranked higher than
66% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ALXN: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
ALXN' s 10-Year Equity to Asset Range
Min: 0.04  Med: 0.70 Max: 0.95
Current: 0.8
0.04
0.95
Interest Coverage 291.32
ALXN's Interest Coverage is ranked lower than
82% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 291.32 )
Ranked among companies with meaningful Interest Coverage only.
ALXN' s 10-Year Interest Coverage Range
Min: 14.38  Med: 178.82 Max: 9999.99
Current: 291.32
14.38
9999.99
F-Score: 6
Z-Score: 31.85
M-Score: -2.50
WACC vs ROIC
2.28%
39.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 33.65
ALXN's Operating margin (%) is ranked higher than
93% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. ALXN: 33.65 )
Ranked among companies with meaningful Operating margin (%) only.
ALXN' s 10-Year Operating margin (%) Range
Min: -10370.21  Med: -138.47 Max: 38.89
Current: 33.65
-10370.21
38.89
Net-margin (%) 25.97
ALXN's Net-margin (%) is ranked higher than
89% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. ALXN: 25.97 )
Ranked among companies with meaningful Net-margin (%) only.
ALXN' s 10-Year Net-margin (%) Range
Min: -10220.86  Med: -128.11 Max: 76.31
Current: 25.97
-10220.86
76.31
ROE (%) 18.97
ALXN's ROE (%) is ranked higher than
91% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. ALXN: 18.97 )
Ranked among companies with meaningful ROE (%) only.
ALXN' s 10-Year ROE (%) Range
Min: -136.75  Med: -26.56 Max: 63.11
Current: 18.97
-136.75
63.11
ROA (%) 15.15
ALXN's ROA (%) is ranked higher than
93% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. ALXN: 15.15 )
Ranked among companies with meaningful ROA (%) only.
ALXN' s 10-Year ROA (%) Range
Min: -45.22  Med: -16.03 Max: 46.71
Current: 15.15
-45.22
46.71
ROC (Joel Greenblatt) (%) 114.48
ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. ALXN: 114.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALXN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -902.5  Med: -209.62 Max: 173.86
Current: 114.48
-902.5
173.86
Revenue Growth (3Y)(%) 39.50
ALXN's Revenue Growth (3Y)(%) is ranked higher than
88% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ALXN: 39.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALXN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -70.5  Med: 39.10 Max: 498.1
Current: 39.5
-70.5
498.1
EBITDA Growth (3Y)(%) 52.40
ALXN's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. ALXN: 52.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALXN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.1  Med: 29.50 Max: 72.8
Current: 52.4
-10.1
72.8
EPS Growth (3Y)(%) 53.00
ALXN's EPS Growth (3Y)(%) is ranked higher than
93% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ALXN: 53.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALXN' s 10-Year EPS Growth (3Y)(%) Range
Min: -15.3  Med: 14.50 Max: 77.3
Current: 53
-15.3
77.3
» ALXN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ALXN Guru Trades in Q2 2014

Jim Simons 245,552 sh (New)
Joel Greenblatt 17,094 sh (+240.11%)
Andreas Halvorsen 2,006,092 sh (+9.23%)
Pioneer Investments 31,934 sh (+1.53%)
Frank Sands 5,279,782 sh (+0.22%)
Steven Cohen 11,700 sh (unchged)
John Burbank Sold Out
Ron Baron 10,145 sh (-0.71%)
Ray Dalio 26,332 sh (-47.72%)
Paul Tudor Jones 1,326 sh (-76.84%)
» More
Q3 2014

ALXN Guru Trades in Q3 2014

Paul Tudor Jones 3,120 sh (+135.29%)
Ron Baron 12,941 sh (+27.56%)
Andreas Halvorsen 2,198,451 sh (+9.59%)
Frank Sands 5,311,488 sh (+0.60%)
Pioneer Investments 30,500 sh (unchged)
Steven Cohen Sold Out
Ray Dalio Sold Out
Jim Simons 206,152 sh (-16.05%)
Joel Greenblatt 1,804 sh (-89.45%)
» More
Q4 2014

ALXN Guru Trades in Q4 2014

Ray Dalio 18,513 sh (New)
Joel Greenblatt 85,974 sh (+4665.74%)
Ron Baron 18,366 sh (+41.92%)
Pioneer Investments 30,795 sh (+0.97%)
Frank Sands 5,267,903 sh (-0.82%)
Frank Sands 5,267,903 sh (-0.82%)
Jim Simons 152,552 sh (-26.00%)
Paul Tudor Jones 1,487 sh (-52.34%)
Andreas Halvorsen 390,271 sh (-82.25%)
» More
Q1 2015

ALXN Guru Trades in Q1 2015

Lee Ainslie 1,350 sh (New)
Ron Baron 41,163 sh (+124.13%)
Paul Tudor Jones 3,231 sh (+117.28%)
Jim Simons 313,952 sh (+105.80%)
Ray Dalio 29,099 sh (+57.18%)
Pioneer Investments 31,941 sh (+3.72%)
Andreas Halvorsen Sold Out
Frank Sands 5,204,296 sh (-1.21%)
Joel Greenblatt 23,261 sh (-72.94%)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Alexion Pharmaceuticals Inc

Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Alexion Pharmaceuticals Inc, Equity Residential, and Tableau Software Inc. Read more...
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY
According to GuruFocus Insider Data, the largest insider sells during the past week were: Oracle Corporation (NYSE:ORCL), Alexion Pharmaceuticals Inc (NASDAQ:ALXN), Waters Corp (NYSE:WAT) and DENTSPLY International Inc (NASDAQ:XRAY). Read more...
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock
The CEO of Alexion Pharmaceuticals Inc (NASDAQ:ALXN), Leonard Bell, sold more than 100,000 shares of company stock Wednesday for nearly $17 million. At a price of $160.71 per share, the sale of 105,000 shares of company stock brought $16,874,551. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 67.60
ALXN's P/E(ttm) is ranked lower than
69% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 43.00 vs. ALXN: 67.60 )
Ranked among companies with meaningful P/E(ttm) only.
ALXN' s 10-Year P/E(ttm) Range
Min: 13.92  Med: 72.61 Max: 1113.68
Current: 67.6
13.92
1113.68
Forward P/E 33.67
ALXN's Forward P/E is ranked lower than
69% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. ALXN: 33.67 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 67.60
ALXN's PE(NRI) is ranked lower than
69% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. ALXN: 67.60 )
Ranked among companies with meaningful PE(NRI) only.
ALXN' s 10-Year PE(NRI) Range
Min: 13.96  Med: 73.08 Max: 1058
Current: 67.6
13.96
1058
P/B 11.21
ALXN's P/B is ranked lower than
81% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ALXN: 11.21 )
Ranked among companies with meaningful P/B only.
ALXN' s 10-Year P/B Range
Min: 3.05  Med: 10.82 Max: 162.14
Current: 11.21
3.05
162.14
P/S 17.57
ALXN's P/S is ranked lower than
60% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. ALXN: 17.57 )
Ranked among companies with meaningful P/S only.
ALXN' s 10-Year P/S Range
Min: 9.66  Med: 17.47 Max: 1115.3
Current: 17.57
9.66
1115.3
PFCF 76.82
ALXN's PFCF is ranked lower than
65% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 45.41 vs. ALXN: 76.82 )
Ranked among companies with meaningful PFCF only.
ALXN' s 10-Year PFCF Range
Min: 40  Med: 63.15 Max: 99999999.99
Current: 76.82
40
99999999.99
POCF 57.40
ALXN's POCF is ranked lower than
67% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 35.29 vs. ALXN: 57.40 )
Ranked among companies with meaningful POCF only.
ALXN' s 10-Year POCF Range
Min: 33.16  Med: 52.69 Max: 83.87
Current: 57.4
33.16
83.87
EV-to-EBIT 55.63
ALXN's EV-to-EBIT is ranked lower than
66% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. ALXN: 55.63 )
Ranked among companies with meaningful EV-to-EBIT only.
ALXN' s 10-Year EV-to-EBIT Range
Min: -98.6  Med: 43.55 Max: 893.9
Current: 55.63
-98.6
893.9
PEG 1.29
ALXN's PEG is ranked higher than
81% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.73 vs. ALXN: 1.29 )
Ranked among companies with meaningful PEG only.
ALXN' s 10-Year PEG Range
Min: 0.68  Med: 1.28 Max: 2.63
Current: 1.29
0.68
2.63
Shiller P/E 123.60
ALXN's Shiller P/E is ranked lower than
78% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 48.33 vs. ALXN: 123.60 )
Ranked among companies with meaningful Shiller P/E only.
ALXN' s 10-Year Shiller P/E Range
Min: 98.32  Med: 133.58 Max: 655.33
Current: 123.6
98.32
655.33
Current Ratio 4.92
ALXN's Current Ratio is ranked higher than
53% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ALXN: 4.92 )
Ranked among companies with meaningful Current Ratio only.
ALXN' s 10-Year Current Ratio Range
Min: 1.38  Med: 7.98 Max: 52.92
Current: 4.92
1.38
52.92
Quick Ratio 4.61
ALXN's Quick Ratio is ranked higher than
54% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. ALXN: 4.61 )
Ranked among companies with meaningful Quick Ratio only.
ALXN' s 10-Year Quick Ratio Range
Min: 1.38  Med: 7.66 Max: 52.92
Current: 4.61
1.38
52.92
Days Inventory 264.48
ALXN's Days Inventory is ranked lower than
84% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 118.28 vs. ALXN: 264.48 )
Ranked among companies with meaningful Days Inventory only.
ALXN' s 10-Year Days Inventory Range
Min: 202.61  Med: 330.15 Max: 959.95
Current: 264.48
202.61
959.95
Days Sales Outstanding 77.25
ALXN's Days Sales Outstanding is ranked lower than
61% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. ALXN: 77.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALXN' s 10-Year Days Sales Outstanding Range
Min: 70.74  Med: 113.85 Max: 451.45
Current: 77.25
70.74
451.45

Valuation & Return

vs
industry
vs
history
Price/Net Cash 38.42
ALXN's Price/Net Cash is ranked lower than
88% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. ALXN: 38.42 )
Ranked among companies with meaningful Price/Net Cash only.
ALXN' s 10-Year Price/Net Cash Range
Min: 1.37  Med: 12.63 Max: 205.55
Current: 38.42
1.37
205.55
Price/Net Current Asset Value 20.17
ALXN's Price/Net Current Asset Value is ranked lower than
81% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. ALXN: 20.17 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALXN' s 10-Year Price/Net Current Asset Value Range
Min: 1.34  Med: 11.78 Max: 2321.5
Current: 20.17
1.34
2321.5
Price/Tangible Book 14.73
ALXN's Price/Tangible Book is ranked lower than
83% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. ALXN: 14.73 )
Ranked among companies with meaningful Price/Tangible Book only.
ALXN' s 10-Year Price/Tangible Book Range
Min: 1.15  Med: 9.03 Max: 82.09
Current: 14.73
1.15
82.09
Price/Projected FCF 5.53
ALXN's Price/Projected FCF is ranked lower than
51% of the 136 Companies
in the Global Biotechnology industry.

( Industry Median: 5.34 vs. ALXN: 5.53 )
Ranked among companies with meaningful Price/Projected FCF only.
ALXN' s 10-Year Price/Projected FCF Range
Min: 4.34  Med: 7.16 Max: 142.19
Current: 5.53
4.34
142.19
Price/Median PS Value 1.00
ALXN's Price/Median PS Value is ranked higher than
59% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. ALXN: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
ALXN' s 10-Year Price/Median PS Value Range
Min: 0.36  Med: 1.16 Max: 59.4
Current: 1
0.36
59.4
Price/Peter Lynch Fair Value 2.70
ALXN's Price/Peter Lynch Fair Value is ranked lower than
55% of the 40 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. ALXN: 2.70 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ALXN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56  Med: 2.83 Max: 4.22
Current: 2.7
0.56
4.22
Price/Graham Number 6.62
ALXN's Price/Graham Number is ranked lower than
75% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. ALXN: 6.62 )
Ranked among companies with meaningful Price/Graham Number only.
ALXN' s 10-Year Price/Graham Number Range
Min: 2.04  Med: 6.61 Max: 22.85
Current: 6.62
2.04
22.85
Earnings Yield (Greenblatt) (%) 1.80
ALXN's Earnings Yield (Greenblatt) (%) is ranked higher than
82% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ALXN: 1.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALXN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 2.10 Max: 3
Current: 1.8
0.1
3
Forward Rate of Return (Yacktman) (%) 50.49
ALXN's Forward Rate of Return (Yacktman) (%) is ranked higher than
95% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 14.59 vs. ALXN: 50.49 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ALXN' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -18.5  Med: 0.20 Max: 75.6
Current: 50.49
-18.5
75.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ALXN.Switzerland, AXP.Germany, 0QZM.UK,
Alexion Pharmaceuticals Inc is a Delaware based company, incorporated in 1992. The Company is a biopharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company is also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. It operates in United States, Europe and Asia Pacific. It competes with companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and in other countries and regions, as well as a growing number of large pharmaceutical companies that are developing biotechnology products. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of products and product candidates, including Soliris, are subject to extensive regulation by governmental authorities in the United States, the European Union and other territories.
» More Articles for ALXN

Headlines

Articles On GuruFocus.com
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Alexion Acquiring Synageva For $8.4 Billion May 09 2015 
Alexion Pharma Downgraded Despite Progress in Pipeline Jan 05 2015 
Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
You Can No Longer Ignore Biotech Feb 07 2014 

More From Other Websites
ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Jul 31 2015
Alexion Pharmaceuticals (ALXN) Earnings Report: Q2 2015 Conference Call Transcript Jul 31 2015
Edited Transcript of ALXN earnings conference call or presentation 30-Jul-15 2:00pm GMT Jul 30 2015
Amgen, Alexion Top Views, But Their Outlooks Differ Jul 30 2015
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 30 2015
Alexion Facing Big Costs, Guidance Disappoints Jul 30 2015
Alexion Pharmaceuticals (ALXN) Stock Gained on Earnings as Guidance Lowered Jul 30 2015
Alexion Misses on Earnings in Q2, 2015 Outlook Revised - Analyst Blog Jul 30 2015
Alexion Pharmaceuticals Inc Earnings Call scheduled for 10:00 am ET today Jul 30 2015
Celgene Corp. Earnings Analysis: By the Numbers Jul 30 2015
Alexion (ALXN) Misses on Q2 Earnings, Revises Outlook - Tale of the Tape Jul 30 2015
Alexion tops Street 2Q forecasts Jul 30 2015
Alexion tops Street 2Q forecasts Jul 30 2015
Alexion Reports Second Quarter 2015 Results Jul 30 2015
Will Rising Costs Hurt Alexion (ALXN) Earnings in Q2? - Analyst Blog Jul 28 2015
Is Gilead Sciences About to Make an Acquisition? Jul 27 2015
JP Morgan Moves Alexion Pharma To Overweight, Says Strensiq And Kanuma Are $1.7B Opportunity Jul 27 2015
What to Expect from Biogen and Celgene Jul 20 2015
4 Large Cap Biotech Stocks to Buy Before Earnings Jul 20 2015
Alexion, Incyte Stage Breakouts Jul 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK